Bantam Vape, LLC, a manufacturer of science-based e-liquid products, has announced that its premarket tobacco product application (PMTA) submission has been accepted by the U.S. Food and Drug Administration (FDA). These applications were for the company’s non-tobacco e-liquids. Bantam first submitted its application for its non-tobacco nicotine e-liquids to the FDA on May 13, 2022. It hopes to receive a marketing order from the agency.
Bantam’s PMTA now moves on to the next step in the FDA’s review process–a preliminary scientific review that will determine whether or not the application has all the required items needed to allow for a more substantive review by the FDA.
“The receipt of this acceptance letter reflects Bantam’s efforts to provide adult consumers with high-quality, science-based e-liquids while upholding our responsibility to restrict youth access and use of these products,” said Bantam spokesperson Anthony Dillon. “Bantam remains supportive of the need for science-based regulation in the e-liquids industry and is proud of the progress of our various PMTAs. We remain confident in the quality and consistency of our products and the science behind them.”
In addition to its application for its non-tobacco e-liquids, Bantam submitted a PMTA in September 2020 for its tobacco-derived e-liquids. The application began its scientific review in August 2021 and to date remains under FDA review.
For the latest news from the FDA, visit bantamvape.com.
Photo: Bantam Vape
